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Abstract
Background: We determined the proportion of the effects of body mass index (BMI) or its categories on
cardiometabolic outcomes mediated through systolic blood pressure (SBP), total cholesterol and fasting glucose.
Methods: Cox regression analyses were performed for incident outcomes among Turkish Adult Risk Factor study
participants in whom the three mediators had been determined (n = 2158, age 48.5 ± 11 years). Over a mean 10.2-years’
follow-up, new coronary heart disease (CHD) developed in 406, diabetes in 284 individuals, and 149 CHD deaths
occurred.
Results: Hazard ratios (HR) of BMI for incident diabetes were no more than marginally attenuated by the 3 mediators
including glucose, irrespective of gender. Compared to “normal-weight”, sex- and age-adjusted RRs for incident CHD of
overweight and obesity were 1.40 and 2.24 (95 % CI 1.68; 2.99), respectively, in gender combined. Only three-tenths of
the excess risk was retained by BMI in men, six-tenths in women. No mediation of glycemia was discerned in males, in
contrast to greatest mediation in females. HR of age-adjusted continuous BMI was a significant but modest contributor
to CHD mortality in each gender. While the BMI risk of CHD death was abolished by mediation of SBP in men, HR
strengthened to over two-fold in women through mediation of fasting glucose.
Conclusions: Mediation of adiposity by 3 traditional factors exhibited among Turkish adults strong gender dependence
regarding its magnitude for CHD risk and the mediation by individual risk factors. Retention of the large part of risk for
diabetes in each sex and for CHD in women likely reflects underlying autoimmune activation.
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Background
Rise in the proportion of overweight and obese individuals
represents the most prominent recent cardiovascular risk
factor in Turkey and worldwide. Many studies have shown
that cardiovascular risk of excess adiposity is mediated
mainly by traditional risk factors such as systolic blood
pressure (SBP), levels of total cholesterol and glucose, or
diabetes [1–4]. The magnitude of the mediation may vary
across races and by gender. In order to appropriately
target the individual risk factors, the effect size of the
mediating factors and the excess residual risk of adiposity
are highly relevant from the public health viewpoint.
The role of BMI in cardiovascular disease in the Asia-
Pacific region has been studied in a meta-analysis [5],
and the association of overweight with increased coron-
ary heart disease (CHD) risk independent of BP and
cholesterol level has been investigated in another meta-
analysis [6]. The most extensive quantification of the
effects of high BMI, and of overweight and obesity on
CHD mediated through SBP, serum cholesterol, and
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glucose, has been in the Global Burden of Disease
(GBD) study [7], analyzing data from 97 prospective
cohort studies. The HR for each 5 kg/m2 higher BMI
was 1.27 for CHD, after adjustment for confounders.
Additional adjustment for the three metabolic risk fac-
tors reduced the HRs to 1.15 indicating that 46 % of the
excess risk of BMI for CHD was mediated by these fac-
tors. SBP was the most important mediator, accounting
for 31 % of the excess risk on CHD. Compared with nor-
mal weight, both overweight and obesity were associated
with significantly increased CHD risk, with 50 % of the
excess risk of overweight and 44 % of the excess risk of
obesity for CHD being mediated by the selected 3 medi-
ators. Authors concluded that, though nearly one half of
excess risk for CHD due to high BMI was mediated
through 3 metabolic risk factors, maintaining optimal
body weight was needed for the full benefits.
The share of Middle Eastern populations in the GBD
meta-analysis comprised less than 0.5 % of the total par-
ticipants and hardly 1 % of the CHD events. Of the
57161 CHD events, 88.6 % were recorded in Western
cohorts. Therein elicited major findings might have lim-
ited applicability for Turkish adults, since differences
may exist in how BMI affects the mediating metabolic
risks in diverse populations. Moreover, sex-stratified
analyses were not provided, an aspect of critical import-
ance among Turks [8]. Thus we undertook the task of
clarifying the effects of the mediating risk factors for
BMI on CHD risk among Turks. Our aim was to deter-
mine, separately in the sexes, the residual risk of inci-
dent nonfatal and fatal CHD of overweight and obesity
after excluding the effects of mediation of blood pres-
sure (BP), glucose and total cholesterol levels. Finally,




The TARF study is a prospective cohort study on the
prevalence of cardiac disease and risk factors in adults in
Turkey carried out biennially since 1990 in 59 communi-
ties scattered throughout all geographical regions of the
country [9]. It comprises a random sample of the Turkish
adult population, representatively stratified for sex, age,
geographical regions and for rural–urban distribution.
New random recruitment forming 15 % of the study sam-
ple was made in 2002/’03. Participants numbering 2287 –
of whom 129 had CHD at baseline– composed the cohort
of the current study. BMI, BP and fasting glucose determi-
nations were available in the surveys encompassing the
10 years from 1997/’98 to 2007. Seventy-three % of partic-
ipants had a baseline in the survey 1997/’98. The sample
did not contain individuals who had been deceased prior
to baseline, and 390 participants with no follow-up were
excluded. The study was approved by the Ethics Commit-
tee of the Istanbul University Medical Faculty. Written
informed consent for participation was obtained from all.
Data were obtained by history of the past years via a ques-
tionnaire, physical examination of the cardiovascular sys-
tem, sampling of blood and recording a resting 12-lead
electrocardiogram.
Measurement of risk factors
BP was measured with an aneroid sphygmomanometer
(Erka, Bad Tölz, Germany) in the sitting position on the
right arm, and the mean of two recordings 5 min apart
was recorded. Height was measured without shoes using
a measuring stick and weight without shoes in light in-
door clothes using a scale. Waist circumference was
measured at the level midway between the lower rib
margin and the iliac crest. Cigarette smoking status was
categorized into never, former and current smokers.
Anyone who reported the use of alcoholic beverages
once a week or more was considered as alcohol user.
Physical activity was graded by the participant himself
into four categories of increasing order with the aid of a
scheme [9].
Blood samples were collected, spun at 1000 g, shipped
to Istanbul and stored in deep-freeze at −75 °C, until ana-
lyzed within weeks. Serum concentrations of glucose, total
cholesterol, fasting triglycerides, low-density lipoprotein
(LDL)- and high-density lipoprotein (HDL)-cholesterol
were determined using Cobas 500 autoanalyzer (Roche
Diagnostic GmbH, Germany). Serum concentrations of
apolipoprotein (apo) B and apoA-I were measured nephe-
lometrically by BN ProSpec analyzer (Siemens Healthcare
Diagnostics, Germany).
Definitions
Participants were classified into three categories: BMI
≤25 kg/m2, overweight (BMI 25.0–29.9 kg/m2), obesity
(BMI ≥30.0 kg/m2). Hypertension was defined as a blood
pressure ≥140 mmHg and/or ≥90 mmHg, and/or use of
antihypertensive medication. Individuals with metabolic
syndrome (MetS) were identified when 3 out of the 5
criteria of the National Cholesterol Education Program
(ATP III) [10] were met, modified for prediabetes (fast-
ing glucose 100–125 mg/dl [11] and further for abdom-
inal obesity using as cutpoint ≥95 cm in men, as
assessed in the Turkish Adult Risk Factor study [12].
Diabetes was diagnosed with the criteria of the American
Diabetes Association, namely by self-report of antidiabetic
medication, or a plasma fasting glucose ≥126 mg/dl [13].
Diagnosis of CHD was based on the presence of angina
pectoris, of a history of myocardial infarction with or
without accompanying Minnesota codes of the ECG [14]
or on a history of myocardial revascularization. Typical
angina and, in women, age >45 years were prerequisite
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for a diagnosis when angina was isolated. ECG changes
of “ischemic type” of greater than minor degree (Codes
1.1–2, 4.1–2, 5.1–2, 7.1) were considered as myocardial
infarct sequelae or myocardial ischemia, respectively.
CHD death comprised death from heart failure of coron-
ary origin or fatal coronary event. Death was ascertained
via information from first-degree relatives, records of
local health personnel and/or the nation-wide Identity
Participation System.
Data analysis
Descriptive parameters were shown as mean ± standard
deviation or in percentages. For several other variables
with skewed distribution, values derived from log-
transformed (geometric) means were used. An SD value
of (for example) 1.7 indicates the factor needed to multi-
ply or divide the mean value to obtain the limits of the
SD. ANOVA analyses and pairwise comparisons with
post hoc Tukey HSD were made to detect significance
across more than two groups; two-sided t-tests and
Pearson’s chi-square tests were used to analyze the dif-
ferences between means and proportions of two groups.
Cox proportional hazard regression analyses of the
BMI categories for outcomes were performed in models
that adjusted basically for (sex and) age and smoking
status. Participants with outcome conditions at baseline
were excluded from regression analyses. The relative risk
(RR) for the three adiposity categories and the hazard
ratio (HR)s for the mediating factors (systolic BP, total
cholesterol and fasting glucose) were estimated and
expressed for each in terms of 1-SD increment. We
adjusted for sex, age, smoking status, and additionally
for the 3 mediators in regard to analyses involving WC.
Residual adiposity risk was estimated as percentage of
excess risk mediated by the 3 risk factors deducted from
the excess risk of the BMI category, which we expressed
also as percentage of excess risk mediated [7, 15]. A
value of p < 0.05 on the two-tail test was considered sta-
tistically significant. Statistical analyses were performed
using SPSS-10 for Windows.
Results
The study sample consisted of 2287 participants (of
whom 1199 female) at age 48.5 ± 11 years at baseline.
Mean age was similar in the sexes. Of the 616 subjects
in the category BMI ≤25 kg/m2, only 67 had BMI
<20 kg/m2. Follow-up ranged from 2 to 16 years with a
mean of 10.2 ± 4.6 years. Total follow-up amounted to
21,980 person-years. Incident CHD manifested in 406,
incident diabetes in 284 persons, and CHD mortality
was identified in 149 (6.9 %) individuals (yielding a CHD
mortality rate of 6.56 [8.0 for men, 5.0 for women] per
1000 person-years).
Baseline characteristics of the sample free of CHD are
presented in Table 1, stratified to BMI categories and
gender. As also seen in Fig. 1, obesity existed only in
19 % of men, but in 44.4 % of women –an odds of 2.3-
fold. Among the 18 variables examined, all but apoA-I
and in men alcohol usage, were significantly different
across the BMI categories. Though HDL-cholesterol was
significantly lower in obesity than in normal-weight in
each gender, apoA-I concentrations were similar. Never
smokers were significantly more prevalent, current
smokers less prevalent in obesity than in normal-weight,
regardless of sex. Pulse pressure was higher in obese
women than obese men (55.3 vs. 50.6 mmHg)
Table 2 shows the prediction of incident CHD by BMI
categories in Cox regression, by gender and adjusted by
the three mediating factors in 3 models. In the model
adjusted only for sex, age and smoking status, over-
weight disclosed an RR of 1.40 compared to normal-
weight, whereas obesity had an HR 2.24 (95 % CI 1.68;
2.99) in gender combined. The addition of systolic BP,
fasting glucose plus LDL- and HDL-cholesterol attenu-
ated the HR of overweight to non-significance, but obes-
ity retained strong significance (RR 1.56). This showed
gender disparity inasmuch as while obesity in men was
no longer significant, it was significant in women with
an RR 1.90 (95 % CI 1.20; 3.02), retaining 61 % of the
excess CHD risk independent of fasting glucose, systolic
BP and total cholesterol.
Substituting abdominal obesity for the two BMI cat-
egories (Additional file 1: Table S1) replicated the
changes in magnitude and sex difference stated for over-
all adiposity. Whereas only 48 % of the CHD risk was
retained by abdominal obesity in men, attenuating the
RR to borderline significance, 64 % of the risk was
retained in women, rendering persistence of independent
significance in RR by abdominal obesity,
Table 3 shows prediction of CHD mortality and inci-
dent diabetes by continuous BMI values in each gender,
adjusted for SBP, total cholesterol and fasting glucose.
For incident diabetes, sex- and age-adjusted BMI was as-
sociated with an HR 1.73 per 1 SD increment. When all
3 mediators were added to the model, the HR of BMI
was reduced merely as little as less than 3 %: to 2.05 in
men and to 1.52 in women.
CHD mortality was, however, determined only by a
significant HR 1.12 by the sex- and age-adjusted BMI.
This effect was fully mediated in men by total choles-
terol and glycemia and was more than offset by SBP.
Women, in contrast, disclosed an inverse mediation ef-
fect by the 3 risk factors, so that HR of BMI rose to 1.26
(95 % CI 1.00; 1.60).
Replacing in model 3, Table 3, HDL-C with apoA-I
(values were missing in 18 % of the sample) showed ten-
dency to protect against CHD in women (p = 0.062) along
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with mild attenuation of the RR of obesity (p = 0.053),
while apoA-I was not protective in men (p = 0.48), age,
SBP and total cholesterol retaining their significant pre-
dictive abilities.
Discussion
This population-based prospective study on middle-aged
Turkish adults seeking the direct and mediated effect of
adiposity on cardiometabolic risk demonstrated following
Table 1 Baseline characteristics of the study sample stratified to BMI categories and gender (n = 2158)
BMI categories ANOVA p-value
BMI ≤25 Overweight Obesity
n Mean SD Mean SD Mean SD
Men 1015 n = 350 n = 473 n = 192
Age, years 1015 47,3 12,9 48,9 11,3 50,5 11,3 ,008
Phys. activity gr., I-IV 1013 2,59 1,07 2,40 1,02 2,31 1,00 ,004
Waist circumf., cm 1012 83,5 7,1 96,3 6,0 106,8 8,7 <0,001
Systolic BP, mmHg 1015 117,5 17,5 128,0 19,7 139,8 24,9 <0,001
Diastolic BP, mmHg 1015 75,0 10,5 82,1 11,4 89,2 14,6 <0,001
T. cholesterol, mg/dl 1015 173,8 35,5 185,4 36,6 194,8 38,8 <0,001
HDL cholest, mg/dl 1011 41,1 13,1 36,3 10,6 35,5 10,0 <0,001
LDL-cholest, mg/dl 994 108,8 31,0 114,8 31,4 119,3 31,7 ,001
Triglycerides, mg/dl 1012 121,7 70 172,0 100,6 194,6 112 <0,001
Apolipoprot.A-I, mg/dl 838 131,9 28 128,7 24,1 131 27,6 ,262
Apolipoprot. B, mg/dl 824 103,8 31,2 110,4 33,8 111,5 30,9 ,015
Fast. glucose, mg/dl 1015 94,7 24,3 97,9 29,8 102,8 31,2 ,007
B mass index, kg/m2 1015 22,5 1,9 27,4 1,35 32,6 2,5 <0,001
Diabetes, yes n, % 1015 10 2,9 25 5,3 19 9,9 0,002
MetS, yes n, % 1015 41 11,7 260 55,0 142 74,0 <0,001
Hypertension, n, % 1015 54 15,4 171 36,2 109 56,8 <0,001
Current, former smoker, n 1011 216; 55 62.2; 15.9 218; 111 46.1; 23.5 81; 47 42.4; 24.6 <0,001
Alcohol usage, yes, n, % 1008 58 16,8 91 19,3 28 14,7 0,332
Women 1143 234 402 507
Age, years 1143 45,0 12,5 47,6 12,1 50,4 10,6 <0,001
Phys. activity gr., I-IV 1135 2,24 ,71 2,18 ,67 2,08 ,67 ,010
Waist circumf., cm 1137 77,3 7,7 88,2 7,9 100,5 9,4 <0,001
Systolic BP, mmHg 1143 118,9 20,7 129,8 24 143,0 26,7 <0,001
Diastolic BP, mmHg 1143 75,0 11,2 82,2 12,7 88,7 14,7 <0,001
T. cholesterol, mg/dl 1143 176,9 37,4 190,7 37,2 198,2 38,7 <0,001
HDL cholest, mg/dl 1139 47,9 13,7 44,7 11,7 43,8 12, 6 <0,001
LDL-cholest, mg/dl 1115 108 32,8 120, 31,3 123,4 34,4 <0,001
Triglycerides, mg/dl 1143 110,7 80,1 131,7 78,9 155,4 88,8 <0,001
Apolipoprot.A-I, mg/dl 937 144,1 31,9 142,6 28,3 144,3 28,8 ,692
Apolipoprot. B, mg/dl 944 103,7 30,7 110,4 37,3 116,3 45,0 ,002
Fast. glucose, mg/dl 1143 96,3 26,7 98 23,9 102,6 30,4 ,005
B mass index, kg/m2 1143 22,6 1,89 27,6 1,4 34,5 3,8 <0,001
Diabetes, yes n, % 1139 7 3,0 15 3,7 53 7 <0,001
MetS, yes n, % 1143 35 15,0 164 40,8 373 73,6 <0,001
Hypertension, n, % 1143 43 18,4 145 36,1 301 59,4 <0,001
Current, former smoker, n, % 1142 77; 9 32,9; 3,8 83; 23 20,6; 5.7 51; 20 10.1; 4.0 <0,001
Alcohol usage, yes, n, % 1138 7 3,0 2 ,5 0 0 <0,001
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findings dependent on type of cardiometabolic condition
and gender. A) BMI determined the development of type-
2 diabetes at a 1.5- to 2-fold HR, more so in men than
women, and was virtually not mediated by a combination
of SBP, total cholesterol and glucose levels. B) Regarding
incident CHD, overweight displayed a non-significant
tendency to confer risk that was little modified in either
gender by the 3 mediators. C) Compared with normal-
weight, obesity imparted a significant ~2-fold CHD risk.
In men, ¾ of this excess risk was mediated especially by
SBP, and by total cholesterol and glucose. In women, in
contrast, 60 % of the excess risk was retained by BMI,
leaving the remainder to the mediation of the major risk
factors. D) BMI, though a significant modest predictor of
CHD mortality, was mediated by the conventional risk
factors in males, but retained substantially greater inde-
pendent risk in females. These findings, collectively, sug-
gest that other determinant factors are mediated by BMI/
obesity for the risk of diabetes and CHD and, in women,
for the risk of CHD by obesity. CHD risk of obesity in
men was largely conferred by SBP-total cholesterol, and
little by obesity.
Noteworthy is that the overall obesity category was pre-
dominated by females whereas the referent “normal-weight”
category was so by males (Additional file 2: Figure S1).
Adipose tissue, particularly tissue from visceral-fat de-
posits, secretes potential mediators in the development
of chronic diseases. Obesity is characterized by abnormal
adipokine production and the activation of several proin-
flammatory signaling pathways, resulting in the induc-
tion of several biological markers of inflammation [16].
Resistin and tumor necrosis factor TNF-α are implicated
in inducing atherogenic adipokines, such as plas-
minogen activating inhibitor-1 and interleukin-6, and
inhibiting adiponectin. TNF-α activates also nuclear
factor-(NF-)kB which may mediate hypertension and
endothelial dysfunction. In obese patients, macrophage
and lymphocyte infiltration in adipose tissue may strongly
contribute to obesity-related metabolic dysfunction and
chronic inflammation [17].
Diabetes risk is overwhelmingly determined by BMI and
little by glucose
Age-standardized adult diabetes prevalence globally rose
since 1980 more rapidly in women than men [18]. The
development of diabetes is recognized to be largely co-
determined by BMI with which our findings concur.
Noteworthy is that added adjustment for fasting glucose
hardly attenuated the HR of BMI for diabetes in either
or both sexes. This may be related to lipoprotein[Lp}(a)-
activated autoimmunity [19] which determines glycemia
and concomitantly mediates rise in BMI. In the meta-
analysis by Singh et al. [20] RRs for 5 kg/m2 higher BMI
for ages 55–64 was 2.32 (2.04–2.63) for diabetes and
ranged for all adult ages from 3 to 1.4. RRs for the esti-
mated effect of BMI were larger in Western cohorts as
compared with Asian cohorts in adults <55 years old. Of
interest was that the effect of BMI on incident diabetes
in Turkish women was only half that found in men. This
may be related to the gender difference existing on
Lp(a)-induced autoimmunity [19]. Of further interest
was that the mediation of systolic BP and total choles-
terol (alike of glucose) was virtually negligible.
CHD risk of overweight little modified by the three
mediators
Elevated peripheral vascular resistance and renal salt
retention due to higher sympathetic nervous system ac-
tivity, angiotensin-aldosterone activity and insulin levels
[21] can lead to hypertension in people with adiposity
which leads also to dyslipidemia. Moreover, enhanced
low-grade inflammation may render insulin resistance
and diabetes [22]. We concur with the global meta-
analysis [7] that the association between adiposity and
CHD is not completely explained by the three mediators
in men and underline that it is far from being explained
in women.
Overweight imparted modest age-adjusted CHD risk
(1.33-fold the “normal” weight); and this was attenuated
mainly by systolic BP. The attenuation via BP and serum
total cholesterol was 45 % in the meta-analysis of the
BMI-CHD Collaborators [6] and was one-half (of the un-
adjusted RR 1.26) via the three mediating risk factors in
the meta-analysis of the Chronic Diseases Collaboration
Fig. 1 Depicts percentages of excess risks of obesity in men and women
for incident coronary heart disease (CHD), type-2 diabetes and overall
mortality. CHD risk is indicated separately also for overweight. It is evident
that obesity in females, as distinct from males, retains substantially greater
risk for CHD mortality and CHD, unmediated by the studied 3 traditional
risk factors
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[7]. RR of the age-adjusted CHD risk in the current study
was also close to the former meta-analysis.
The two-fold CHD risk of obesity is mediated by risk
factors largely in men, modestly in women
Excess CHD risk, compared with normal weight, showed
a steep rise in the obesity category relativeto the over-
weight one; sex-, age- and smoking-adjusted RRs in
combined gender were, namely, 2.24 and 1.40, respect-
ively. In comparison to the meta-analysis on global
cohorts [7], this basic excess risk displayed gender
difference insofar as the RR was by one-third higher in
men, but nearly two-fold in women. Though mediation
by the 3 risk factors (with 55 % of the excess risk) was
closely similar to that in the global cohorts, gender dis-
parity in the current study was more prominent in the
mediation by the 3 risk factors: whereas 70 % of the
excess BMI risk was thus mediated in men, 60 % was
retained by BMI in women. A gender difference of the
BMI-mediated risk was not reported in three meta-
analyses [5–7] in which sex-stratified analysis was, how-
ever, not reported.
Table 2 Cox regression models for the prediction of incident CHD by BMI categories and mediators, by gender
Total Men Women
HR 95 % CI HR 95 % CI HR 95 % CI
404/2153a 185/1011a 219/1142a
Sex, female 0.93 0.73; 1.18
Age, 11 years 1.78 1.64; 1.96 1.82 1.59; 2.08 1.76 1.56; 2.00
Current vs. never smoking 1.60 1.24; 2.07 1.58 1.11; 2.25 1.65 1.13; 2.42
Former vs. never smoking 1.28 0.91; 1.79 1.25 0.83; 1. 09 1.32 0.67; 2.58
Overweight 1.40 1.05; 1.85 1.44 1.01; 2.05 1.40 0.87; 2.24
Obesity 2.24 1.68; 2.99 2.00 1.34; 3.00 2.48 1.59; 3.87
Model 1
Sex, female 0.83 0.68; 1.02
Age, 11 years 1.57 1.43; 1.73 1.56 1.34; 1.78 1.57 1.37; 1.78
Overweight 1.18 0.89; 1.57 1.17 0.82; 1.67 1.19 0.74; 1.92
Obesity 1.61 1.20; 2.17 1.37 0.89; 2.10 1.79 1.14; 2.80
Systolic BP, 25 mmHg 1.37 1.24; 1.51 1.52 1.27; 1.82 1.31 1.17; 1.48
Model 2
Sex, female 0.87 0.71; 1.07
Age, 11 years 1.64 1.51; 1.80 1.71 1.49; 1.96 1.61 1.40; 1.84
Overweight 1.26 0.95; 1.67 1.31 0.92; 1.86 1.27 0.79; 2.03
Obesity 1.87 1.41; 2.50 1.69 1.12; 2.55 2.10 1.35; 3.25
Total cholesterol, 40 mg/dl 1.23 1.11; 1.37 1.25 1.07; 1.45 1.23 1.07; 1.42
Fasting glucose, 25 mg/dl 1.12 1.04; 1.20 1.02 0.92; 1.13 1.20 1.05; 1.32
Model 3 399/2098a 183/987a 216/1111a
Sex, female 0.92 0.72; 1.18
Age, 11 years 1.62 1.45; 1.78 1.61 1.39; 1.86 1.61 1.38; 1.84
Current vs. never smoking 1.67 1.28; 2.17 1.68 1.17; 2.42 1.61 1.09; 2.38
Former vs. never smoking 1.30 0.93; 1.83 1.23 0.82; 1.72 1.47 0.75; 2.90
Overweight 1.19 0.90; 1.59 1.19 0.82; 1.72 1.31 0.81; 2.11
Obesity 1.56 1.15; 2.12 1.30 0.83; 2.04 1.90 1.20; 3.02
LDL-cholesterol, 32 mg/dl 1.14 1.04; 1.26 1.13 0.98; 1.31 1.16 1.02; 1.32
HDL-cholesterol, 12 mg/dl 0.89 0.80; 0.99 0.96 0.82; 1.12 0.83 0.72; 0.96
Fasting glucose, 25 mg/dl 1.12 1.04; 1.21 1.05 0.92; 1.19 1.20 1.08; 1.32
Systolic BP, 25 mmHg 1.38 1.25; 1.52 1.52 1.27; 1.82 1.32 1.17; 1.49
Overweight and obesity prevailed in 45.6 and 18.9 % in men, in 35.2 and 44.4 % in women
Referent in adiposity categories was BMI ≤25 kg/m2
aIncident cases/whole sample Diabetes prevailed in 100 (46 M/54 W) participants at baseline
Bold numbers denote significant values
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The retained CHD risk by BMI may be due to path-
ways of systemic inflammation, endothelial dysfunction,
and thrombogenic factors. Alike the meta-analysis find-
ings, the largest mediation was found for systolic BP,
followed by total cholesterol and least for fasting
glucose. Obesity mediation by the individual risk factors
was markedly different across sexes inasmuch as gly-
cemia did not mediate any BMI risk in men, in contrast
to demonstrating the largest mediation (with 14 %) in
women. This distribution of obesity-mediated risk across
the sexes as well as the retention of the majority of the
obesity risk in women support the notion of autoimmune
process activated by obesity being far more common in
females than males [19]. It is the autoimmune activation
(induced by oxidative stress) and thrombo-embolic events
rather than BP or cholesterolemia that lead to fatal and
non-fatal CHD.
BMI modest determinant of CHD mortality
The sex- and age-adjusted continuous BMI variable was a
significant modest contributor to HR for CHD mortality;
yet this risk was fully abolished by mediation of systolic BP
in men, indicating this factor assumed the main determin-
ant of CHD mortality. In contrast, the HR was strength-
ened to over two-fold in women through mediation of
fasting glucose, implicating that impaired fasting glucose
(IFG) protected Turkish women against CHD death. This
is in agreement with our previous report [23] that IFG sta-
tus in non-diabetic people without MetS is associated with
a less adverse cardiovascular risk profile and reduced future
CHD risk, lest modulated by the developed MetS, especially
in women in whom serum Lp(a), linked inversely to
HOMA, is the likely modulator.
The modest magnitude of HR herein is in line with no
effects of overweight on cardiovascular mortality [24], or
with overall mortality in a meta-analysis [25]. In con-
trast, in the Prospective Studies Collaboration [26] 5
units of BMI revealed 40 % excess vascular mortality risk
above the optimal BMI 22.5-25 kg/m2; below this range,
BMI was inversely related to overall mortality.
Sex-modulated risk of fatal and nonfatal CHD imparted
by obesity
Excess risk of age- and smoking-adjusted obesity was
larger by one-half in women than men. This is at some
variance from the findings of a large pooled analysis on
1.4 million individuals [20] in which effects by age, sex
or global region of major metabolic risk factors on car-
diovascular disease and diabetes were evaluated. At the
age group 55–64 years, the RR was largest for systolic
Table 3 Cox regression models for the prediction of sex- and- age-adjusted CHD mortality and incident diabetes by 1SD of body
mass index adjusted also for mediators, by gender
Total Men Women
HR (95 % CI) p HR (95 % CI) p HR (95 % CI) p
CHD mortality 146/2158 86/1015 60/1143
Body mass index, 5 kg/m2 1.12 (1.10–1.14) <0.001 1.11 (1.09–1.13) 0.001 1.14 (1.11–1.17) <0,001
Adj. Systolic BP 1.14 (0.95–1.37) 0.16 0.96 (0.72–1.28) 0.81 1.31 (1.03–1.66) 0,025
Adj. total cholesterol 1.23 (1.05–1.45) 0.010 1.05 (0.81–1.37) 0.70 1.14 (1.11–1.17) <0,001
Adj. fasting glucose 1.22 (1.03–1.44) 0.021 1.04 (0.80–1.36) 0.76 1.38 (1.12–1.72) 0,003
Adj. SBP & T Chol. 1.11 (0.93–1.34) 0.25 0.94 (0.71–1.26) 0.70 1.27 (0.99–1.62) 0,051
Adj. SBP & FPG 1.12 (0.93–1.35) 0.21 0.93 (0.70–1.24) 0.63 1.30 (1.03–1.64) 0,025
Adj. T Chol & FPG 1.19 (1.00–1.41) 0.050 1.11 (0.78–1.33) 0.90 1.34 (1.07–1.67) 0,008
Adjusted for all 3 factors 1.10 (0.91–1.32) 0.31 0.91 (0.68–1.22) 0.55 1.26 (1.00–1.60) 0,050
Incident diabetes 284/2136 146/1014 138/1122
Body mass index, 5 kg/m2 1.73 (1.54–1.93) <0.001 2.11 (1.75–2.54) 0.001 1.56 (1.35–1.79) <0,001
Adj. Systolic BP 1.71 (1.52–1.93) <0.001 2.13 (1.73–2.63) 0.001 1.54 (1.32–1.79) <0,001
Adj. total cholesterol 1.71 (1.53–1.91) 0.001 2.06 (1.70–2.49) 0.001 1.56 (1.35–1.79 0,001
Adj. fasting glucose 1.71 (1.52–1.91) 0.001 2.10 (1.73–2.55) 0.001 1.55 (1.34–1.78 0,001
Adj. SBP & T Chol. 1.70 (1.50–1.92) 0.001 2.09 (1.69–2.58) 0.001 1.53 (1.32–1.79) 0,001
Adj. SBP & FPG 1.68 (1.49–1.90) <0.001 2.09 (1.69–2.58) 0.001 1.52 (1.31–1.77) <0,001
Adj. T Chol & FPG 1.69 (1.51–1.90) 0.001 2.03 (1.67–2.48) 0.001 1.55 (1.34–1.78) 0,001
Adjusted for all 3 factorsa 1.67 (1.48–1.89) <0.001 2.05 (1.65–2.54) 0.001 1.52 (1.31–1.77) <0,001
Female sex was protected against diabetes at HR 0.58 (0.45; 0.75)
1 SD considered here for: systolic BP 25 mmHg, total cholesterol 40 mg/dl, glucose 25 mg/dl
aGlucose was the only other significant determinant of diabetes
Numbers in bold denote significant values
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BP with respect to hypertensive HD or stroke, for BMI
regarding diabetes or CHD, and at much lower effect
size for fasting glucose in regard to CHD or stroke. Pro-
portional effects declined with age, were generally con-
sistent by sex, and differed little by region. However,
effects of BMI on diabetes were larger in Western com-
pared with Asian cohorts in younger adults [20].
In regard to BMI-mediated CHD risk of fasting glu-
cose and systolic BP, a clear sex disparity was evident:
Women had a significant risk through glucose (by 15 %
higher than men), while men had such through systolic
BP (by 20 % higher). We have evidence that these
features are largely gene-dependent. The TT genotype of
the CYP19A1 polymorphism encoding the aromatase
enzyme involved in the final step of estrogen synthesis
showed, namely, interaction with narrow waist girth for
hypertension only in men, independent of age and BMI
[27]. In Caucasian US women, an interaction between
the risk allele of the FTO rs8050136 polymorphism
mediated by BMI and low physical activity yielded
increased cardiovascular disease risk [28].
Implications relate both to the prevention of CHD and
DM. Coronary prevention programs should take into
account the role of sex and be modified for sex. While
addressing the mediators with measures including antihy-
pertensive and lipid-lowering medication may largely be
effective in men, addressing the mediators in women will
alleviate only slightly the prevention problem. Major im-
provement in obesity and related proinflammatory state is
required for the CHD prevention. As regards prevention of
type-2 diabetes, our findings indicate that the overwhelm-
ing portion of the risk can be reduced only by weight loss
and improvement in the related oxidative stress (mediated
by Lp(a)-activated autoimmunity), regardless of gender.
Limitations and strength
Our basic regression models did not adjust for certain
confounding factors such as socioeconomic state, physical
activity grade, or diet; this might have affected the BMI-
mediated CHD risk, though not to a great extent. Analysis
stratified to sex which substantially generated novel know-
ledge constitutes a major strength. Despite the fact that,
due to lack of an oral glucose tolerance test, some cases of
actual diabetes may have been missed, analyzing the BMI-
mediated effects also for diabetes and CHD mortality in
the same cohort represents further strength.
Conclusions
Gender, fatal or nonfatal CHD or diabetes modulated in
middle-aged Turkish adults the mediation of BMI by 3
traditional risk factors, or the retention of residual excess
risk by BMI, respectively. Hardly any mediation was
observed with respect to diabetes. Compared with
normal-weight, obesity imparted a significant over 2-fold
CHD risk. In men, this was extensively mediated while in
women, 60 % of the excess CHD risk and virtually the en-
tire risk for CHD death were retained by BMI. These find-
ings can be explained by autoimmune activation occurring
in a greater proportion of females, a process mainly in-
duced by oxidative damage to Lp(a) in a setting of excess
adiposity.
Additional files
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Additional file 2: Table S1. Cox regression models for the prediction
of incident CHD by presence of abdominal obesity and three mediators,
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